Trial Profile
CINJ 070501(NJ 1205): A Phase II Study of Imatinib Mesylate and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 17 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 17 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect record.